The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Effect of the GABA B agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors
Open accessAbstract
Background and aims: A subset of patients with gastro-oesophageal reflux disease (GORD) with refractory symptoms during therapy with proton pump inhibitors (PPIs), have persistent non-acid duodeno-gastro-oesophageal reflux (duodenal reflux). The aim of the present study was to investigate the effect of the GABA B receptor agonist baclofen, which was shown to inhibit the occurrence of transient lower oesophageal sphincter relaxations (TLOSRs) in patients with persistent non-acid duodenal reflux during PPI therapy. Methods: Patients were eligible for the study if they had persistent reflux symptoms, normal pH monitoring, and pathological Bilitec monitoring during PPI treatment. Upper gastrointestinal endoscopy and reflux symptom score were performed at the beginning of the study. Baclofen 5 mg three times daily was associated with treatment, and was increased by 5 mg every fourth day until a maintenance dose of 20 mg three times daily was reached. A reflux symptom questionnaire, ambulatory pH monitoring, and Bilitec monitoring were repeated four days later while PPI and baclofen were continued. All data are given as mean (SEM) or median (interquartile range) and were compared using the Student’s t test or the Mann-Whitney U test. Results: Sixteen patients (11 women, mean age 46 (3) years) with persistent heartburn or regurgitation for at least three months, in spite of PPI therapy, were included in the study. Erosive oesophagitis was present in seven patients (five with grade 1, two with grade 2). Under PPI therapy alone, all patients had normal acid exposure (0.3 (0.05; 2.2)% of the time) but pathological duodenal reflux exposure (13.8 (11.8; 15.5)% of the time). After addition of baclofen 20 mg three times daily, acid exposure was similar (0.4 (0.15; 2.3)% of the time; NS) but duodenal reflux had significantly decreased (6.1 (0.8; 10.3)% of the time; p<0.05). The number of duodenal reflux episodes and the number of longlasting duodenal reflux episodes (>5 minutes) was decreased, respectively, from 23 (14.5; 34) to 12 (5; 21) (p = 0.06) and from 5 (3; 8) to 2 (0.5;4.5) (p<0.05). The cumulative severity score for 14 reflux symptoms decreased from 10.3 (1.7) to 5.8 (1.3) (p<0.01). Four patients reported mild side effects of nausea or drowsiness. Conclusions: The GABA B receptor agonist baclofen improves duodenal reflux and associated reflux symptoms that persist during PPI therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of Gastroesophageal Reflux in Patients with Reflux Esophagitis
Dodds, W. J., Dent, J., Hogan, W. J., Helm, J. F., Hauser, R., Patel, G. K., & Egide, M. S. (1982) · New England Journal of Medicine · doi:10.1056/nejm198212163072503 · Cited by 995
Healing and relapse of severe peptic esophagitis after treatment with omeprazole
Hetzel, D. J., Dent, J., Reed, W. D., Narielvala, F. M., Mackinnon, M., McCarthy, J. H., Mitchell, B., Beveridge, B. R., Laurence, B. H., Gibson, G. G., et al. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90162-x · Cited by 777
Vela, M. F., Camacho-Lobato, L., Srinivasan, R., Tutuian, R., Katz, P. O., & Castell, D. O. (2001) · Gastroenterology · doi:10.1053/gast.2001.24840 · Cited by 613
Klinkenberg-Knol, E. C., Nelis, F., Dent, J., Snel, P., Mitchell, B., Prichard, P., Lloyd, D., Havu, N., Frame, M. H., Romàn, J., et al. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70135-1 · Cited by 534
Duodenogastroesophageal reflux: Relationship to pH and importance in Barrett's esophagus
Champion, G., Richter, J. E., Vaezi, M. F., Singh, S., & Alexander, R. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90123-6 · Cited by 455
Zhang, Q., Lehmann, A., Rigda, R., Dent, J., & Holloway, R. H. (2002) · Gut · doi:10.1136/gut.50.1.19 · Cited by 351
Lidums, I., Lehmann, A., Checklin, H., Dent, J., & Holloway, R. H. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70408-2 · Cited by 321
Prevalence of Symptoms Suggestive of Gastroesophageal Reflux Disease in an Adult Population
Isolauri, J., & Laippala, P. (1995) · Annals of Medicine · doi:10.3109/07853899509031939 · Cited by 319
Mechanisms of gastroesophageal reflux in ambulant healthy human subjects
Schoeman, M. N., Tippett, M. D., Akkermans, L. M. A., Dent, J., & Holloway, R. H. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90011-x · Cited by 312
Composition of the postprandial refluxate in patients with gastroesophageal reflux disease
Sifrim, D. (2001) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)02391-1 · Cited by 221
Self-citation
Cited by
Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease
Katz, P. O., Gerson, L. B., & Vela, M. F. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.444 · Cited by 1,767
ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease
Katz, P. O., Dunbar, K. B., Schnoll-Sussman, F. H., Greer, K. B., Yadlapati, R., & Spechler, S. J. (2022) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001538 · Cited by 1,038
Molecular Structure and Physiological Functions of GABABReceptors
Bettler, B., Kaupmann, K., Mosbacher, J., & Gassmann, M. (2004) · Physiological Reviews · doi:10.1152/physrev.00036.2003 · Cited by 924
Systematic review: proton‐pump inhibitor failure in gastro‐oesophageal reflux disease – where next?
FASS, R., SHAPIRO, M., DEKEL, R., & SEWELL, J. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02531.x · Cited by 394
ACG Practice Guidelines: Esophageal Reflux Testing
Hirano, I., & Richter, J. E. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00936.x · Cited by 351
Metadata
- Authors
- Koek, G. H., Sifrim, D., Lerut, T., Janssens, J., & Tack, J.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2003-09-11
- Volume
- 52
- Issue
- 10
- Pages
- 1397-1402
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2143285572
- Cited by
- 295
- References
- 18
- FWCI
- 15.21
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of the GABA B agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. https://app.cochat.ai/papers/10.1136/gut.52.10.1397
- The paper
- Koek, G. H., Sifrim, D., Lerut, T., Janssens, J., & Tack, J. (2003). Effect of the GABA B agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut. https://doi.org/10.1136/gut.52.10.1397
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.